AB0190 SSGJ-613 RELIEVES PAIN AND REDUCES THE RISK OF ACUTE FLARES IN PATIENTS WITH GOUT: RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PHASE II STUDY

医学 痛风 双盲 急性疼痛 随机对照试验 内科学 麻醉 替代医学 安慰剂 病理
作者
He Zou,Y. Xue,Qunfang Zhou,Yanli Xu,Hongyun Huang
出处
期刊:Annals of the Rheumatic Diseases [BMJ]
卷期号:83: 1330-1330 被引量:1
标识
DOI:10.1136/annrheumdis-2024-eular.1697
摘要

Background:

Gouty arthritis is a common inflammatory arthritis caused by the deposition of monosodium urate (MSU) crystals in joints with the prevalence of 1% to 3% in China. Interleukin 1-β (IL-1β) is a key mediator of acute gouty flares, and anti-IL-1β therapy has been proven to be an important option for the treatment of gouty arthritis. However, no IL-1β inhibitors are available in China. Therefore, the effectiveness of IL-1β inhibitors in Chinese patients with gout remains unclear.

Objectives:

This is a double-blind, double-dummy, active-controlled phase II study to assess the efficacy and safety of SSGJ-613, a fully human anti-interleukin 1β monoclonal antibody, in Chinese patients with gout.

Methods:

Key inclusion criteria were: patients aged 18 to 65 years and meeting the ACR criteria of gout; presence of an acute Gouty Arthritis flare for no longer than 7 days; baseline pain intensity ≥50 mm on the 0 to 100 mm VAS. Eligible patients were subsequently randomized 1:1:1 to the two SSGJ-613 groups and the active control group to receive a single dose of SSGJ-613, 200, or 300 mg subcutaneously; or Betamethasone 1mL Intramuscularly. The efficacy of SSGJ-613 in pain relief and flares prophylaxis was assessed by the change of VAS scores from baseline after 72 hours of dosing and the percentage of patients developing new flares within 12 weeks after single administration of SSGJ-613. Safety was assessed through monitoring of adverse events (AEs) and laboratory testing.

Results:

A total of 90 patients were enrolled in this study. At baseline, the mean VAS scores for the targeted joints were 72.4mm, 66.8mm, and 67.4mm in the SSGJ-613 200 mg, SSGJ-613 300 mg, and Betamethasone 1mL groups, respectively. 72 hours after administration, all treatment groups exhibited significant pain relief, with VAS scores changes from baseline (mean ± standard deviation) being -45.8 ± 17.88 mm, -40.4 ± 17.35 mm, and -48.2 ± 15.90 mm for the SSGJ-613 200 mg group, SSGJ-613 300 mg group, and Betamethasone, respectively. There were no statistical differences between the two SSGJ-613 doses and Betamethasone(p=0.4533 and 0.0848 for SSGJ-613 200mg and 300mg, respectively). More importantly, the percentage of patients developing new flares was remarkably lower for all SSGJ-613 groups compared with Betamethasone, with 16.7% (5/30) and 14.3% (4/28) for the SSGJ-613 200mg and 300mg doses, respectively, versus 51.6% (16/31) for Betamethasone 1mL. Regrading inflammatory factors, hsCRP, SAA, and ESR decreased rapidly in all three groups at 72 hours after dosing, with SSGJ-613 doses showing more pronounced reduction on hsCRP and SAA than Betamethasone. Safety profile was comparable between SSGJ-613 and Betamethasone, with a relatively low incidence in SSGJ-613 groups.

Conclusion:

These results demonstrated that a single injection of SSGJ-613 could achieve rapid pain relief similar to that of steroids in Chinese patients with gout and provide effective prophylaxis against flares. To confirm the efficacy and safety of SSGJ-613 in Chinese gout patients, further trials will be initiated soon.

REFERENCES:

NIL.

Acknowledgements:

NIL.

Disclosure of Interests:

Hejian Zou: None declared, Yu Xue: None declared, Qinghong Zhou Employed Sunshine Guojian Pharmaceutical (Shanghai) Co.,Ltd, Yuyu Xu Employed by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Haomin Huang Employed by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
在水一方的应助被科研通管家采纳,获得100
刚刚
脑洞疼的应助被科研通管家采纳,获得10
1秒前
wanci的应助被科研通管家采纳,获得10
1秒前
ding的应助被科研通管家采纳,获得10
1秒前
1秒前
121213完成签到,获得积分10
1秒前
共享精神的应助被科研通管家采纳,获得10
1秒前
wanci的应助被科研通管家采纳,获得10
1秒前
思源的应助被科研通管家采纳,获得10
1秒前
刘肥肥完成签到,获得积分10
1秒前
田様的应助被科研通管家采纳,获得10
1秒前
2秒前
领导范儿的应助被科研通管家采纳,获得10
2秒前
我是老大的应助被科研通管家采纳,获得10
2秒前
李爱国的应助被学做科研采纳,获得10
2秒前
桐桐的应助被科研通管家采纳,获得10
2秒前
Kelly完成签到 ,获得积分10
2秒前
脑洞疼的应助被科研通管家采纳,获得10
2秒前
香蕉觅云的应助被科研通管家采纳,获得10
2秒前
2秒前
hZC完成签到,获得积分20
2秒前
2秒前
ding的应助被rjx采纳,获得10
2秒前
2秒前
稳重的元瑶完成签到,获得积分10
3秒前
彭于晏的应助被abcde采纳,获得10
3秒前
2026奇点1013完成签到,获得积分10
3秒前
沉静连虎完成签到,获得积分10
4秒前
joeqin完成签到,获得积分0
4秒前
4秒前
ZZ关注了科研通微信公众号
5秒前
欢喜完成签到 ,获得积分10
6秒前
无私藏鸟发布了新的文献求助10
6秒前
6秒前
千春发布了新的文献求助20
7秒前
yqy完成签到,获得积分10
7秒前
elisa828发布了新的文献求助10
8秒前
8秒前
xyysee完成签到,获得积分10
9秒前
lujing完成签到 ,获得积分10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190698
求助须知:如何正确求助?哪些是违规求助? 9577768
关于积分的说明 21854810
捐赠科研通 7789827
什么是DOI,文献DOI怎么找? 3436452
关于科研通互助平台的介绍 2560302
邀请新用户注册赠送积分活动 2483169